1	Title: Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated
2	individuals granting breadth in neutralizability and tolerance against variants
3	Authors: Yu Nakagama, <sup>a,b</sup> Katherine Candray, <sup>a,b,c</sup> Natsuko Kaku, <sup>a,b</sup> Yuko Komase, <sup>d</sup> Maria-
4	Virginia Rodriguez-Funes, <sup>e</sup> Rhina Dominguez, <sup>f</sup> Tomoya Tsuchida, <sup>g</sup> Hiroyuki Kunishima, <sup>h</sup>
5	Etsuko Nagai, <sup>i</sup> Eisuke Adachi, <sup>i</sup> Dieudonné Mumba Ngoyi, <sup>j</sup> Mari Yamasue, <sup>k</sup> Kosaku Komiya, <sup>k</sup>
6	Kazufumi Hiramatsu, <sup>k</sup> Naoto Uemura, <sup>k</sup> Yuki Sugiura, <sup>I</sup> Mayo Yasugi, <sup>m,n,o</sup> Yuka Yamagishi, <sup>p</sup>
7	Hiroshige Mikamo, <sup>p</sup> Satoshi Shiraishi, <sup>q</sup> Takehiro Izumo, <sup>r</sup> Sachie Nakagama, <sup>a,b</sup> Chihiro
8	Watanabe, <sup>a,b</sup> Yuko Nitahara, <sup>a,b</sup> Evariste Tshibangu-Kabamba, <sup>a,b</sup> Hiroshi Kakeya, <sup>b,s</sup>
9	Yasutoshi Kido <sup>a,b</sup>
10	Author institutional affiliations:
10 11	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan
10 11 12	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
10 11 12 13	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>b</sup> Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka
10 11 12 13 14	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>b</sup> Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
10 11 12 13 14 15	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>b</sup> Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>c</sup> Centro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El
10 11 12 13 14 15 16	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>b</sup> Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>c</sup> Centro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El Salvador
10 11 12 13 14 15 16 17	Author institutional affiliations: <sup>a</sup> Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>b</sup> Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan <sup>c</sup> Centro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El Salvador <sup>d</sup> Department of Respiratory Internal Medicine, St. Marianna University, Yokohama Seibu

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 19 <sup>e</sup> National Rosales Hospital, San Salvador, El Salvador
- 20 <sup>f</sup> El Salvador National Institute of Health, San Salvador, El Salvador
- <sup>g</sup> Division of General Internal Medicine, St. Marianna University School of Medicine,
- 22 Kawasaki, Japan
- 23 <sup>h</sup> Department of Infectious Diseases, St. Marianna University School of Medicine,
- 24 Kawasaki, Japan
- <sup>1</sup>Department of Infectious Diseases and Applied Immunology, Institute of Medical Science,
- 26 The University of Tokyo, Tokyo, Japan
- 27 <sup>j</sup> Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
- 28 <sup>k</sup> Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of
- 29 Medicine, Oita, Japan
- 30 <sup>1</sup>Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School
- 31 of Medicine, Kyoto, Japan
- <sup>m</sup> Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
- <sup>n</sup> Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
- <sup>o</sup> Osaka International Research Center for Infectious Diseases, Osaka Metropolitan
- 35 University, Osaka, Japan
- 36 <sup>p</sup> Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan

- <sup>q</sup> Department of Respiratory Medicine, Osaka City Juso Hospital, Osaka, Japan
- 39 <sup>s</sup> Department of Infection Control Science, Graduate School of Medicine, Osaka
- 40 Metropolitan University, Osaka, Japan
- 41 Keywords: SARS-CoV-2, Antibody maturation, Avidity, Neutralization breadth, Variants of
- 42 concern
- 43 **Running title:** High-avidity SARS-CoV-2 IgG protectivity
- 44 Address for correspondence (alternate):
- 45 Yasutoshi Kido, MD, PhD (Yu Nakagama, MD, PhD)
- 46 Department of Parasitology, Graduate School of Medicine, Osaka Metropolitan University,
- 47 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
- 48 E-mail: kidoyasu@omu.ac.jp (nakagama.yu@omu.ac.jp)
- 49 Type of manuscript
- 50 Major article
- 51

#### 52 Abstract—word count 246

- 53 Background
- 54 The durability and cross-neutralizability of protective antibodies against evolving SARS-
- 55 CoV-2 variants are primary concerns in mitigating (re-)exposures. The role of antibody
- 56 maturation, the process whereby selection of higher avidity antibodies augments host
- 57 immunity, to determine SARS-CoV-2 neutralizability was investigated.
- 58 Methods

59 Sera collected from SARS-CoV-2 convalescent individuals at 2- or 10-months after 60 recovery, and BNT162b2 vaccine recipients at 3 or 25 weeks post-vaccination, were 61 analyzed. Anti-spike IgG avidity was measured on a urea-treated ELISA platform. 62 Neutralizing ability of antibodies was assessed by surrogate virus neutralization. Fold 63 change between variant and wild-type antigen neutralizability was calculated to infer 64 breadth of neutralizability.

65 Results

66 Compared with early-convalescence, the avidity index of late-convalescent sera was 67 significantly higher (median 37.7 (interquartile range 28.4–45.1) vs. 64.9 (57.5–71.5), p < 68 0.0001), indicative of progressive antibody maturation extending months beyond acute-69 phase illness. The urea-resistant, high-avidity fraction of IgG was best predictive of

70	neutralizability (Spearman's r = 0.49 vs. 0.67 for wild-type; 0.18-0.52 vs. 0.48-0.83 for
71	variants). Higher-avidity convalescent sera showed greater cross-neutralizability against
72	SARS-CoV-2 variants (p < 0.001 for Alpha; p < 0.01 for Delta and Omicron). Vaccinees
73	experienced delayed maturation kinetics, translating to limited breadth of neutralizability at
74	week-25 post-vaccination which was only comparable to that of early-convalescence.
75	Conclusions
76	Avidity maturation grants broader neutralizability that is resilient against emerging SARS-
76 77	Avidity maturation grants broader neutralizability that is resilient against emerging SARS- CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal
76 77 78	Avidity maturation grants broader neutralizability that is resilient against emerging SARS- CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish herd immunity, understanding the variable longitudinal evolutions of

#### 81 Text—word count 2993

#### 82 Introduction

83 Given the reported coronavirus disease 2019 (COVID-19) re-infections and 84 vaccine breakthrough infections, it is unlikely that convalescent or vaccinated individuals 85 will attain lifelong immune protection [1,2]. Therefore, the magnitude of partial immunity 86 those individuals acquire is an important issue. In the convalescent phase and thereafter, 87 circulating levels of neutralizing IgG that target the SARS-CoV-2 receptor binding domain 88 (RBD) are highly correlated with residual protectivity [3,4]. However, the durability of anti-89 spike IgGs and their potential cross-neutralizability against rapidly evolving severe acute 90 respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are primary concerns in 91 mitigating future re-exposures [5].

Avidity maturation is the biological process whereby antigen-driven selection of higher affinity antibodies augments the host's long-lasting protective immunity. Continuous antigen presentation at germinal centers promotes the fine-tuning of the antibody's complementarity toward the epitope. The kinetics and potential implications of maturing antibody avidity in the context of immune protection against SARS-CoV-2 and its emerging variants of concern (VOCs) remains to be fully elucidated [6–8]. In the present study, we correlated the kinetics of serum antibody avidity maturation, which followed SARS-CoV-2

99	natural infections, as well as vaccine administrations, to the magnitude and breadth of in
100	vitro neutralizability. Our observations provide a logical perspective on the variable
101	durability and resilience of the two building blocks needed for the acquisition of 'hybrid
102	immunity'.

- 103
- 104 Materials and Methods

#### 105 Human subjects and sample collection

106 Total 462 convalescent individuals, who had recovered from COVID-19 [9], were 107 recruited at Osaka Metropolitan University and collaborating institutions preceding the 108 emergence of the SARS-CoV-2 VOCs, comprising a mixed cohort from different regions, 109 where the predominant genotypes belonged to B.1 or B.1.1 lineages [10,11]. Serum 110 samples from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine were collected at 111 week 3 and week 25 after the first dose. Analyses were conducted in accordance with the 112 1964 Declaration of Helsinki and its later amendments. This research was approved by the 113 Ethical Committee of Osaka Metropolitan University Graduate School of Medicine (#2020-114 003). All participants provided written informed consent prior to enrollment. 115

116 Anti-spike IgG measurement

117	Abbott SARS-CoV-2 IgG II Quant assays (Abbott, IL, USA, 6S6023) were run in
118	accordance with the manufacturer's instructions. Anti-SARS-CoV-2 IgG enzyme-linked
119	immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany, El 2606–9601) was
120	performed in accordance with the manufacturer's instructions.

121

```
122 Avidity ELISA
```

123 Serum samples were tested for their avidity towards the SARS-CoV-2 spike 124 antigen using an ELISA-based assay (Euroimmun, Lübeck, Germany, El 2606–9601) [12]. 125 Samples were processed, in an extra pair of wells, with additional urea treatment (5.5 M for 126 10 min at 37°C) following the incubation of the spike antigen-coated plate with serum 127 samples, to detach any low-avidity antibodies. The avidity index (AI) was calculated as 128 follows: AI = { $(OD_{450} \text{ of sample with 5.5 M urea)} - (OD_{450} \text{ of negative control with 5.5 M}$ 129 urea)} / { $(OD_{450} \text{ of sample without urea}) - (OD_{450} \text{ of negative control without urea})} \times 100$ 130 [%]. Serum samples were diluted 1:101 for analysis, except for the post-vaccine sera, 131 which required a higher dilution of 1:201 to bring the OD<sub>450</sub> signals into linear range. 132

### 133 Neutralizing ability

134 Neutralizing ability against wild-type (WT) and VOC SARS-CoV-2 was quantified

135 using the GenScript SARS-CoV-2 sVNT (GenScript, Piscataway, NJ, USA, L00847-A), a 136 competition ELISA-based surrogate virus neutralization test (sVNT). Obtained signals have been shown to strongly correlate with the results of the conventional live-virus 137 138 neutralization test [13,14]. The assay protocol followed that of the manufacturer's 139 instructions. Serum samples and controls were pre-incubated to neutralize WT RBD (WT; 140 GenScript, Z03594), or B.1.1.7 (Alpha; GenScript, Z03595), B.1.617.2 (Delta; GenScript, Z03614), or B.1.1.529 (Omicron; GenScript, Z03730) RBD variants conjugated with 141 142 peroxidase. (%inhibition) horseradish The inhibition rate was calculated as 143 follows: %inhibition =  $\{1 - (OD_{450} \text{ of sample}) / (OD_{450} \text{ of negative control})\} \times 100 [\%].$ 

144

#### 145 Breadth of neutralizability

For quantitative assessment of the serum antibodies' abilities to cross-neutralize SARS-CoV-2 and its variants, the sVNT %inhibition values were converted to the linearly scaled WHO International Standard units, IU/mL [15,16]. We obtained a standard inhibitory dose-response curve by fitting the log-transformed IU/mL concentration values and their corresponding %inhibition data, obtained from testing four-fold serially diluted WHO International Standard (20/136) in the sVNT, to a four-parameter logistic equation (GraphPad Prism, version 9). The neutralizing titer (IU/mL) of the participants' serum

153	samples, tested at optimized dilutions (up to 1:30, adjusted to bring the OD <sub>450</sub> signals into
154	quantitative range of the standard curves), was converted from sVNT %inhibition data by
155	interpolation from the standard curve per different RBD antigen. The fold changes in
156	neutralizing titer between the VOCs and WT ( $NT_{Alpha}/NT_{WT}$ , $NT_{Delta}/NT_{WT}$ , and
157	$NT_{Omicron}/NT_{WT}$ ) were calculated to serve as the index for the 'breadth of neutralizability'.
158	Similar indices have served as quantitative measures of relative neutralizing potency
159	towards VOC strains [17].
160	
161	Statistical analysis
162	Differences in titer, avidity, and the magnitude/breadth of neutralizing ability of
163	sera were tested by Mann-Whitney test. For the longitudinal anti-spike IgG titer plot, a
164	linear fit was performed, and Pearson's correlation coefficient was calculated. Spearman's
165	correlation coefficient was calculated to assess the strength of the correlation between
166	antibody titer and in vitro neutralizability. P-values less than 0.05 were considered

167 statistically significant.

168

169 Results

170 Serum anti-SARS-CoV-2 antibodies decay, while maturing in avidity, over time

171	As recurrently reported, serum levels of circulating anti-spike IgG showed
172	longitudinal decline in titer in SARS-CoV-2 convalescent individuals (Figure 1, panel A,
173	Pearson's r = $-0.28$ , p = 0.049) [18]. To further investigate the qualitative evolution of serum
174	antibodies, representative subsets of sera matched by their total anti-spike IgG titers
175	(Figure 1, panel B, median OD <sub>450</sub> 1.12 (IQR 0.93–1.25) vs. 1.09 (IQR 0.89–1.26), <i>p</i> = 0.98)
176	were selected from early- and late-convalescent (n = 29, median 8 (IQR 7–9) weeks and n
177	= 26, median 37 (IQR 36-40) weeks post-onset of symptoms, respectively) phases, and
178	compared of their serum antibody avidity characteristics. Polyclonal antibodies present in
179	the late-convalescent sera were more avid against the SARS-CoV-2 spike antigen, and
180	thus their $OD_{450}$ were relatively resistant to urea treatment (Figure 1, panel B). The
181	difference in maturity of convalescent sera was reflected in the avidity index (AI), with that
182	of late-convalescent sera demonstrating higher Als (Figure 1, panel C, median Al 37.7 (IQR
183	28.4–45.1) vs. 64.9 (IQR 57.5–71.5), $p < 0.0001$ ), indicating a progressive maturation
184	process that extends months beyond the acute phase of COVID-19.

185

## 186 Higher-avidity antibodies exert broadened neutralizability against VOCs

187 Next, we investigated the functional consequences of enhanced antibody avidity.
188 Compared with the raw OD<sub>450</sub> values (Figure 2, panel A, upper), the urea-resistant OD<sub>450</sub>

signals from the avidity ELISA (Figure 2, panel A, lower) better correlated with the inhibition

rate (%inhibition) obtained from the surrogate sVNT. The results indicated a central role for

high-affinity anti-spike IgG antibodies in determining in vitro neutralizability against SARS-191 192 CoV-2 WT and variant RBDs. 193 We next tested the hypothesis that serum antibody avidity determines the 194 tolerability against RBD variations. As previously reported, the Alpha, Delta, and Omicron 195 variants were more resistant to neutralization by convalescent sera, showing attenuated 196 inhibition rates in the sVNT (Figure 2, panel B). To further compare the cross-neutralizability 197 of individual sera against different VOCs, in other words the 'breadth of neutralizability', we attempted a linear scale conversion of the neutralizing titer by modifying previously 198 199 employed methods [15]. Briefly, the neutralizing titer [IU/mL] of each convalescent sample 200 was computed from their %inhibition values [%], through interpolation from standard curves 201 that were generated by testing serially-diluted WHO International Standard (20/136) sera 202 (Figure 3, panel A). The 'breadth of neutralizability' was expressed as the NT against the 203 Alpha, Delta, and Omicron VOC RBDs (NT<sub>Alpha</sub>, NT<sub>Delta</sub>, and NT<sub>Omicron</sub>, respectively) relative 204 to the NT against the WT RBD (NTwt) in fold changes. Interestingly, when NTs against 205 SARS-CoV-2 VOCs were plotted against that of WT, with respect to the serum antibody's

206 AI, sera of higher AIs tended to show higher NT<sub>Alpha</sub>, NT<sub>Delta</sub>, and NT<sub>Omicron</sub> values relative to

189

190

207	$NT_{WT}$ (Figure 3, panel B). Next, the fold change in NT against SARS-CoV-2 VOCs relative
208	to the WT was compared between low- (below the 50th percentile) and high-avidity (50th
209	percentile and above) serum samples. Higher-avidity sera showed greater fold change in
210	NT across the different SARS-CoV-2 VOCs (Figure 3, panel C). Altogether, the results
211	indicated that sera of higher AIs exhibited enhanced breadth of neutralizability and better
212	tolerated the variations in SARS-CoV-2 RBD.
213	
214	Vaccinees experience lesser extent of antibody maturation compared with
215	convalescents
216	The variable kinetics of serum antibody avidity maturation between natural
217	infection immunity and vaccine-elicited immune responses were assessed through analysis
218	of sera from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine (vaccinees). Sera
219	collected from vaccinees at week 3 (n = 9) and week 25 (n = 8) after the first dose were
220	matched for their total anti-spike IgG titers (median $OD_{450}$ 1.37 (IQR 1.23–1.90) vs. 1.48
221	(IQR 1.20–1.75), $p = 1.0$ ), and their Als were further compared with those of convalescent
222	individuals (Figure 4, panel A). Serum antibodies present in the sera of week-25 vaccinees
223	demonstrated significantly higher AIs compared with those of week-3 vaccinees (median
224	44.2 (IQR 38.3–47.4) vs 23.4 (IQR 16.9–26.6), $p = 0.0002$ ), indicating that the second dose

225	of the vaccine had boosted the hosts' maturation of antibody avidity. However, the Als of
226	week-25 (approximate month 6) vaccinees were still only equivalent to those of month-2
227	early-convalescents, depicting a substantial lag in the avidity maturation process unique to
228	the vaccine-elicited immune response (Figure 4, panel B).
229	
230	Contribution of the matured IgG fraction to neutralizability among vaccinees
231	Interestingly, in contrast to the convalescent sera and the week-25 vaccinee sera,
232	the neutralizability of the sera of week-3 vaccinees showed a relatively weak correlation
233	(Spearman's r = 0.52, $p$ = 0.16) with their urea-resistant anti-spike IgG titer. The correlation
234	was rather strong (Spearman's r = 0.87, $p < 0.01$ ) when the levels of neutralizability were
235	plotted against total anti-spike IgG titers. This indicates that high-avidity antibodies
236	contribute less to neutralizability early in the vaccine response and become a stronger
237	determinant only after the second dose (Spearman's $r = 0.71$ , $p = 0.06$ ). Reflecting their still
238	insufficient degree of maturation, the breadth of neutralizability of the week-25 vaccinees'
239	sera was limited to an extent comparable to that of early-convalescent sera (Figure 4, panel
240	C).

241

242 Discussions

243	Antibody avidity maturation in COVID-19 convalescents was observed as an
244	ongoing process that surprisingly extended months beyond the acute phase. This finding
245	supports the notion that SARS-CoV-2 proteins persist in tissues to continuously fuel the
246	germinal centers for antigen presentation, even during late convalescence [19]. More
247	importantly, the high-avidity neutralizing IgGs, which are the result of continuous B-cell
248	evolution, remain in the circulation of late convalescents, fortifying for viral re-encounters by
249	exerting enhanced cross-neutralizability against emerging SARS-COV-2 variants.
250	In theory, immature plasma cells produce antibodies that possess
251	conformationally flexible antigen-binding surfaces, which at the cost of lowered specificity
252	and affinity, are capable of recognizing diverse antigens (poly-reactivity hypothesis) [20]. In
253	contrast, mature plasma cells produce antibodies of preorganized and rigid paratopes so
254	as to take more energetically favorable configurations with improved complementarity
255	against epitopes [21]. This general tendency towards paratope rigidification upon avidity
256	maturation, while favorable in terms of enhancing specificity, is seemingly detrimental for
257	broad cross-reactivity. In the case of SARS-CoV-2-neutralizing antibodies, however, our
258	results show that high-avidity antibodies exert broader protection against evolving variants,
259	granting long-lasting protective immunity. This paradoxical relationship between affinity
260	maturation and the broadening in reactivity of SARS-CoV-2-neutralizing antibodies is

261	worthy of note. The molecular basis of B-cell evolution is explained by the acquisition of
262	somatic hypermutations [22]. The aforementioned rigidification of paratopes is only one
263	possible consequence of such somatic hypermutations. Mutations may lead to increased
264	buried surface area upon complex formation, strengthening antibody-antigen binding. B-
265	cells may alternatively acquire amino acid substitutions that result in better complementarity
266	of the antigen binding site. Additive molecular contacts at the paratope-epitope interface,
267	through the addition of novel polar or hydrophobic bonds, may also underlie the better
268	complementarity [23]. The increase in variety of the structural determinants shall decrease
269	the dependency of the paratope-epitope interaction on specific amino acid residues [24].
270	Thus, the latter diverse biophysical mechanisms of antibody affinity maturation all provide
271	explanations to the tolerability of high-affinity antibodies against SARS-CoV-2 variants.
272	Given that the majority of the world's population has relied largely on the SARS-
273	CoV-2 vaccines for immunological protection, our secondary interest was how the vaccine-
274	elicited immune responses were different from natural infection-acquired immunity. The
275	kinetics of affinity maturation of SARS-CoV-2-specific antibodies have recently been shown
276	to correlate with the longevity of immune protection following natural SARS-CoV-2 infection
277	[25-27]. The here observed higher potency of the high-avidity antibodies in neutralizing
278	SARS-CoV-2 may counter the longitudinal decay in quantity and explain the durability of

279 infection-acquired immune protection. Interestingly, compared with natural infection, we 280 observed a substantial delay in the maturation process of vaccine-elicited antibodies. This 281 was accompanied by still insufficient cross-neutralizability against SARS-CoV-2 variants 282 even 6 months after vaccination. Large-scale clinical trials in real-world settings have 283 shown greater protection associated with infection-acquired immunity than with vaccine-284 elicited immune responses [28,29]. The present study further enriches the evidence for and 285 provides an immunological basis to the greater protection associated with infection-286 acquired immunity. Additionally, the urea-resistant fraction of the antibody titer was 287 predictive of neutralizability only following the second dose of the vaccine. In contrast to the limited variety of epitopes recurrently targeted across convalescent individuals [30], the 288 289 vaccine-elicited immune response is mapped to a broadened epitope landscape [31,32]. 290 During the initial response to the SARS-CoV-2 vaccine, the majority of urea-resistant 291 signals obtained from our avidity ELISA were possibly from a widely dispersed, non-292 neutralizing antibody repertoire that still dominated the week-3 vaccinees' sera. The second 293 vaccine dose seemingly facilitated the positive selection of neutralizing over non-294 neutralizing epitopes. Collectively, the dynamics of epitope selection, as well as avidity 295 maturation, seem to radically differ among vaccinees and convalescents [33].

296 Furthermore, circulating IgG may serve as sources of passive

297	immunotherapeutics [34]. In such a context, their extent of maturity may affect cross-
298	neutralizability and immunotherapy outcome. Immunotherapy using convalescent sera has
299	unfortunately remained investigational for COVID-19, though expected beneficial for those
300	with deficient active immunity [35,36]. To mitigate the emergence of immune-escaping
301	variants in future pandemics, assessing avidity to stratify the potency of donated sera may
302	be a reasonable strategy for effective immunotherapy.
303	Limitations of the present study include: (i) the serum samples were not serial
304	collections from individuals, (ii) the cellular compartment was not studied, which also plays
305	decisive roles in immune protection, and (iii) the observation period of vaccinees was
306	limited, so the long-term consequences remain elusive.
307	In conclusion, the present study showed that the continuous process of avidity
308	maturation, extending beyond late convalescence, grants broader neutralizability and
309	robust protection that stand resilient against emerging SARS-CoV-2 variants. With
310	immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish
311	herd immunity, understanding the longitudinal evolution of vaccine-induced immune
312	responses and the incremental protective effects of booster vaccinations, that are to be
313	also repeated in convalescent individuals ('hybrid immunity'), remains critical.
314	

### 315 Funding

316	This research was supported by the Japan Agency for Medical Research and
317	Development [grant numbers JP20jk0110021 to Y.N., JP20wm0125003 and
318	JP20he1122001 to Y.K.]; the Japan Society for the Promotion of Science KAKENHI
319	[21K09078 to N.K., 22K15927 to Y.N.]; and the Osaka Metropolitan University Strategic
320	Research Grant [grant number OCU-SRG2021_YR09 to Y.N.]. The authors also received
321	support from the Osaka Metropolitan University Special Reserves Fund for COVID-19 and
322	the Shinya Yamanaka Laboratory COVID-19 Private Fund.
323	
324	Acknowledgments
325	The authors would like to thank all participants of the study and, for technical
326	assistance, Mrs. Mika Oku from Osaka Metropolitan University. Data acquisition was partly
327	performed at the Research Support Platform, Graduate School of Medicine, Osaka
328	Metropolitan University.
329	

330 Conflicts of Interest

Y.N. and Y.K. report equity ownership of Quantum Molecular Diagnostics, an
 Osaka Metropolitan University spinout targeting infectious diseases to develop innovative

diagnostics. Y.N. and Y.K. also report receiving financial support outside of this work from

334 Abbott Japan LLC, Japan.

#### 336 References

- 337 [1] Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-
- 338 CoV-2 variants. N Engl J Med, 2021;384:2212–2218.
- 339 https://doi.org/10.1056/nejmoa2105000.
- 340 [2] To KK-W, Hung IF-N, Ip JD, et al. Coronavirus Disease 2019 (COVID-19) Re-infection
- 341 by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain
- 342 confirmed by whole genome sequencing. Clin Infect Dis, 2020;2019:1–6.
- 343 https://doi.org/10.1093/cid/ciaa1275.
- 344 [3] Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
- 345 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med,
- 346 2021;27:1205–1211. https://doi.org/10.1038/s41591-021-01377-8.
- 347 [4] Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated
- 348 health care workers. N Engl J Med, 2021;385:1474–1484.
- 349 https://doi.org/10.1056/nejmoa2109072.
- 350 [5] Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-
- 351 CoV-2 and prevention of reinfection. Nat Rev Immunol, 2021;21:395–404.
- 352 https://doi.org/10.1038/s41577-021-00550-x.
- 353 [6] Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective

354 immunity towards SARS-CoV-2. Int J Infect Dis, 2021;106:61–64.

- 355 https://doi.org/10.1016/j.ijid.2021.01.061.
- 356 [7] Bauer G, Struck F, Schreiner P, Staschik E, Soutschek E, Motz M. The challenge of
- 357 avidity determination in SARS-CoV-2 serology. J Med Virol, 2021;93:3092–3104.
- 358 https://doi.org/10.1002/jmv.26863.
- 359 [8] Nakagama Y, Nitahara Y, Kaku N, Tshibangu-Kabamba E, Kido Y. A dual-antigen
- 360 SARS-CoV-2 serological assay reflects antibody avidity. J Clin Microbiol,
- 361 2022;60:e0226221. https://doi.org/10.1128/JCM.02262-21.
- 362 [9] Adachi T, Ayusawa M, Ujiie M, et al. Novel coronavirus infection COVID-19 medical
- 363 practice guidelines. Version 7.2. Available at:
- 364 https://www.mhlw.go.jp/content/000936623.pdf (accessed 1 July 2022).
- 365 [10] Nakagama Y, Komase Y, Candray K, et al. Serological testing reveals the hidden
- 366 COVID-19 burden among health care workers experiencing a SARS-CoV-2 nosocomial
- 367 outbreak. Microbiol Spectr, 2021;9:e0108221. https://doi.org/10.1128/Spectrum.01082-
- 368 21.
- 369 [11] Nakagama Y, Rodriguez-Funes MV, Dominguez R, et al. Cumulative seroprevalence
- 370 among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador,
- 371 Central America. Clin Microbiol Infect, 2022;S1198-743X(22)00333-0. doi:

372 10.1016/j.cmi.2022.06.020.

- 373 [12] Pichler D, Baumgartner M, Kimpel J, et al. Marked increase in avidity of SARS-CoV-2
- 374 antibodies 7–8 months after infection is not diminished in old age. J Infect Dis, 2021:1–7.
- 375 https://doi.org/10.1093/infdis/jiab300.
- 376 [13] Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based
- 377 on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat
- 378 Biotechnol, 2020;38:1073–1078. https://doi.org/10.1038/s41587-020-0631-z.
- 379 [14] Mariën J, Michiels J, Heyndrickx L, et al. Evaluation of a surrogate virus neutralization
- 380 test for high-throughput serosurveillance of SARS-CoV-2. J Virol Methods,

381 2021;297:114228. https://doi.org/10.1016/j.jviromet.2021.114228.

- 382 [15] Taylor SC, Hurst B, Martiszus I, et al. Semi-quantitative, high throughput analysis of
- 383 SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune
- 384 response antibodies post infection/vaccination. Vaccine, 2021;39:5688–5698.
- 385 https://doi.org/10.1016/j.vaccine.2021.07.098.
- 386 [16] National Institute for Biological Standards and Control. First WHO International Standard
- 387 for anti-SARS-CoV-2 immunoglobulin, human. (NIBSC code: 20/136) Available at:
- 388 https://www.nibsc.org/documents/ifu/20-136.pdf (accessed 1 July 2022).
- 389 [17] Moriyama S, Adachi Y, Sato T, et al. Temporal maturation of neutralizing antibodies in

390 COVID-19 convalescent individuals improves potency and breadth to circulating SARS-

- 391 CoV-2 variants. Immunity, 2021;54:1841-1852.e4.
- 392 https://doi.org/10.1016/j.immuni.2021.06.015.
- 393 [18] Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.
- 394 Nature, 2021;591:639–644. https://doi.org/10.1038/s41586-021-03207-w.
- 395 [19] Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2.
- 396 Nature, 2021;591:639–644. https://doi.org/10.1038/s41586-021-03207-w.
- 397 [20] Furukawa K, Akasako-Furukawa A, Shirai H, Nakamura H, Azuma T. Junctional amino
- 398 acids determine the maturation pathway of an antibody. Immunity, 1999;11:329–338.
- 399 https://doi.org/10.1016/S1074-7613(00)80108-9.
- 400 [21] Manivel V, Sahoo NC, Salunke DM, Rao KVS. Maturation of an antibody response is
- 401 governed by modulations in flexibility of the antigen-combining site. Immunity,
- 402 2000;13:611–620. https://doi.org/10.1016/S1074-7613(00)00061-3
- 403 [22] Victora GD, Nussenzweig MC. Germinal centers. Annu Rev Immunol, 2012;30:429–457.
- 404 https://doi.org/10.1146/annurev-immunol-020711-075032
- 405 [23] Mishra AK, Mariuzza RA. Insights into the structural basis of antibody affinity maturation
- 406 from next-generation sequencing. Front Immunol, 2018;9:117.
- 407 https://doi.org/10.3389/fimmu.2018.00117.

#### 408 [24] Muecksch F, Weisblum Y, Barnes CO, et al. Affinity maturation of SARS-CoV-2

- 409 neutralizing antibodies confers potency, breadth, and resilience to viral escape
- 410 mutations. Immunity, 2021;54:1853-1868.e7.
- 411 https://doi.org/10.1016/j.immuni.2021.07.008.
- 412 [25] Luo YR, Chakraborty I, Yun C, Wu AHB, Lynch KL. Kinetics of severe acute respiratory
- 413 syndrome coronavirus 2 (SARS-CoV-2) antibody avidity maturation and association with
- 414 disease severity. Clin Infect Dis, 2021;73:e3095–e3097.
- 415 https://doi.org/10.1093/cid/ciaa1389.
- 416 [26] Löfström E, Eringfält A, Kötz A, et al. Dynamics of IgG-avidity and antibody levels after
- 417 Covid-19. J Clin Virol, 2021;144:104986. https://doi.org/10.1016/j.jcv.2021.104986.
- 418 [27] Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody
- 419 responses and duration of immunity: a longitudinal study. Lancet Microbe, 2021;2:e240–
- 420 e249. https://doi.org/10.1016/S2666-5247(21)00025-2.
- 421 [28] Gazit S, Shlezinger R, Perez G, et al. Severe acute respiratory syndrome coronavirus 2
- 422 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity,
- 423 reinfections versus breakthrough infections: a retrospective cohort study. Clin Infect Dis,
- 424 2022;2:1–7. https://doi.org/10.1093/cid/ciac262.
- 425 [29] Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19

426	vaccination and previous infection. N Engl J Med, 2022;386:1207–1220.
-----	---

- 427 https://doi.org/10.1056/nejmoa2118691.
- 428 [30] Tong P, Gautam A, Windsor IW, et al. Memory B cell repertoire for recognition of
- 429 evolving SARS-CoV-2 spike. Cell, 2021:1–12. https://doi.org/10.1016/j.cell.2021.07.025.
- 430 [31] Nitahara Y, Nakagama Y, Kaku N, et al. High-resolution linear epitope mapping of the
- 431 receptor binding domain of SARS-CoV-2 spike protein in COVID-19 mRNA vaccine
- 432 recipients. Microbiol Spectr, 2021;9 e0096521. https://doi.org/10.1128/spectrum.00965-
- 433 21.
- 434 [32] Greaney AJ, Loes AN, Gentles LE, et al. Antibodies elicited by mRNA-1273 vaccination
- 435 bind more broadly to the receptor binding domain than do those from SARS-CoV-2
- 436 infection. Sci Transl Med, 2021;13:1–13. https://doi.org/10.1126/scitranslmed.abi9915.
- 437 [33] Wang Z, Muecksch F, Schaefer-Babajew D, et al. Naturally enhanced neutralizing
- 438 breadth against SARS-CoV-2 one year after infection. Nature, 2021;595:426–431.
- 439 https://doi.org/10.1038/s41586-021-03696-9.

440 [34] Tang J, Lee Y, Ravichandran S, et al. Epitope diversity of SARS-CoV-2 hyperimmune

- 441 intravenous human immunoglobulins and neutralization of variants of concern. iScience,
- 442 2021;24:103006. https://doi.org/10.1016/j.isci.2021.103006.

443 [35] Takakuwa T, Nakagama Y, Yasugi M, et al. Discrepant antigen-specific antibody

444		responses causing SARS-CoV-2 persistence in a patient receiving B-cell-targeted
445		therapy with rituximab. Intern Med, 2021;60:3827–3831.
446		https://doi.org/10.2169/internalmedicine.7884-21.
447	[36]	Takita M, Yoshida T, Tsuchida T, et al. Low SARS-CoV-2 antibody titers may be
448		associated with poor clinical outcomes for patients with severe COVID-19. Sci Rep,
449		2022;12:9147. https://doi.org/10.1038/s41598-022-12834-w.
450		

#### **Figure legends**

(A)



(B)



459 (C)



460 461

462 Figure 1. Evolution of anti-SARS-CoV-2 IgG in convalescent individuals. A) Anti-spike IgG 463 levels of individuals observed across the convalescent phase, and their linear fit (solid red 464 line) with 95% confidence intervals (dashed red lines). B) Resistance of the OD<sub>450</sub> signal 465 against urea treatment in subsets of sera from early- (n = 29) and late-convalescent (n = 466 26) samples, matched by total anti-spike IgG titers. C) Avidity index of antibodies present in 467 early- (n = 29) and late-convalescent (n = 26) sera. OD<sub>450</sub>, optical density at 450 nm. 468 Statistical significance: \*\*\*\**p* < 0.0001.

#### (A)





(B) 



476 Figure 2. Central role of high-avidity IgG in neutralizing SARS-CoV-2.

477	A) Neutralizability of antibodies present in early- (n = 29) and late-convalescent sera (n =
478	26) against wild-type and variant SARS-CoV-2, as measured by surrogate virus
479	neutralization, and plotted against total (upper) and urea-resistant, high-avidity anti-spike
480	IgG titers (lower). B) Resistance of SARS-CoV-2 variants against neutralization by
481	convalescent sera. OD <sub>450</sub> , optical density at 450 nm. Statistical significance: *** $p$ < 0.001,
482	**** <i>p</i> < 0.0001.







(B)





(C)



493 Figure 3. Enhanced neutralization breadth of higher-avidity anti-SARS-CoV-2 IgG.

- A) Four-parameter logistic standard curves for conversion of inhibition rates to neutralizing antibody titers in WHO International Standard units, IU/mL. B) Cross-neutralizability of convalescent sera against the Alpha (left), Delta (middle), and Omicron variants (right). The samples' avidity indices are depicted according to the color scale shown. C) Relative inhibition potency towards SARS-CoV-2 variants indexed to the wild-type neutralizing titer, indicating the breadth of neutralizability per serum. Statistical significance: \*\**p* < 0.01, \*\*\**p*
- 500 < 0.001.
- 501

(A)



(B)



508 (C)



511 Figure 4. Functional evolution of anti-SARS-CoV-2 IgG in recipients of the BNT162b2 512 SARS-CoV-2 mRNA vaccine.

513 A) Resistance of the OD<sub>450</sub> signal against urea treatment in subsets of sera from vaccine 514 recipients at week 3 (n = 9) and week 25 (n = 8) post-vaccination, matched by total anti-515 spike IgG titers. B) Avidity index of antibodies present in week-3 (n = 9) and week-25 (n = 516 8) vaccinees in comparison with convalescent individuals. C) Relative inhibition potency of 517 week-25 vaccinee sera (n = 8) towards SARS-CoV-2 variants plotted against that of 518 convalescent individuals. OD450, optical density at 450 nm. Statistical significance: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. 519

**(A)** 

## **(B)**





**(A)** 

# (B)



**(A)** 



Avidity index (%)

75

50



